Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;184(5):791-792.
doi: 10.1111/bjd.19570. Epub 2021 Mar 18.

Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis

T-F Tsai  1
Affiliations
Comment

Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis

T-F Tsai. Br J Dermatol. 2021 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Reich K, Körber A, Mrowietz U et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol 2021; https://doi.org/10.1111/bjd.19398
    1. Phung M, Ighani A, Georgakopoulos JR et al. Off-label high-dose secukinumab for the treatment of moderate-to-severe psoriasis. J Cutan Med Surg 2019; 23:391-3.
    1. Thaçi D, Puig L, Reich K et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. J Am Acad Dermatol 2019; 81:1405-9.
    1. Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73:27-36.
    1. Bissonnette R, Luger T, Thaçi D et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32:1507-14.

Substances